PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV

Poster Psoriasis
P 33
Long-term treatment with ustekinumab does not compromise the immune
response to T-cell dependent or T-cell independent vaccines in patients with
moderate to severe psoriasis: A comparison of ustekinumab-treated versus
untreated psoriasis patients
C. Brodmerkel 1
R. Langley 2
K. Papp 3
M. Bourcier 4
Y. Poulin 5
V. Ho 6
L. Guenther 7
M.C. Hsu 1
P.O. Szapary 1
1 Janssen R&D, Spring House, PA, USA
2 Dalhousie University, Halifax, NS, Canada
3 Probity Medical Research, Waterloo, ON, Canada
4 Dermatology Clinic, Moncton, NB, Canada
5 Centre Dermatologique du Quebec Metropolitain, Quebec, Canada
6 University of British Columbia, Vancouver, BC, Canada
7 The Guenther Dermatology Research Centre, London, ON, Canada
Objective: The impact of long-term continuous ustekinumab(UST)(anti-IL12/23p40
mAb) treatment on the ability of patients to mount a response to pneumococcal
vaccine (T-cell independent response) and tetanus toxoid (T-cell dependent response)
was assessed.
Methods: This study was a comparison of patients treated with UST (> 3 yrs), during
the long-term extension of the Phase 3 PHOENIX 2 trial (n=60), to 'control' patients with
moderate-to-severe psoriasis not receiving systemic therapy (n=56). Patients were
vaccinated with 23-valent pneumococcal vaccine and tetanus (Tdap vaccine). Serum
samples were collected pre-vaccination and 4 wks post-vaccination and assessed for
antibody responses to the vaccinations.
Results: Results showed no differences in the ability of UST-treated patients to mount
a sufficient response to pneumococcal or tetanus toxoid vaccination compared to
controls. The majority of patients in both groups achieved >2-fold increase from
pre-vaccination to post-vaccination antibody levels in at least 7 of 14 serotypes of the
pneumococcal vaccine (96.6% UST-treated vs. 92.6% untreated control). 84.7% of
patients in the UST-treated group achieved at least a 4-fold increase in antibody against
tetanus toxoid vs. 77.8% in the control group. In an ex vivo T-cell stimulation assay, no
differences were detected in response to anti-CD3/CD28 or tetanus toxoid between
patients in the UST-treated group and control group.
83